Certified by Founder
Lodge
Endogenex
start up
United States
- PLYMOUTH, MN
- 26/06/2024
- Series C
- $88,000,000
Endogenex, in partnership with Mayo Clinic, aims to revolutionize treatment options for individuals with type 2 diabetes (T2D). Endogenex’s innovations focus on resetting the body’s metabolic signaling system by harnessing its natural regenerative capabilities to improve metabolic function. Through the development of the ReCET™ System and the novel application of precise, controlled, non-thermal pulsed electric fields, Endogenex is establishing a new era in treatment options for people living with T2D, helping patients regain control of their blood glucose levels and slow disease progression.
Endogenex is a privately held, clinical-stage company based in Minneapolis, MN.
- Industry Medical Equipment Manufacturing
- Website https://www.endogenex.com/
- LinkedIn https://www.linkedin.com/company/endogenexinc/
dazzle ai | $8,000,000 | (Jan 7, 2026)
Tesoro XP, Inc. | $5,400,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)
Array Labs | $20,000,000 | (Jan 7, 2026)
Lyte | $107,000,000 | (Jan 7, 2026)
Lucidean | $18,000,000 | (Jan 7, 2026)
CHAMP | $55,000,000 | (Jan 7, 2026)
Truemed | $34,000,000 | (Jan 7, 2026)
Coinbax | $4,200,000 | (Jan 7, 2026)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ciphero | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)